- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06202521
Phase II, Double Blind, Randomized Trial of CX-4945 in Viral Community Acquired Pneumonia
January 1, 2024 updated by: Senhwa Biosciences, Inc.
Evaluation of the Safety and Efficacy of Silmitasertib (CX-4945) in Combination With Standard of Care (SOC) for Treating Patients With Community-Acquired Pneumonia (CAP) Associated With SARS-CoV-2 and Influenza Viral Infections
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated pneumonia.
The subjects will be recruited into two domains, including SARS-CoV-2 and influenza virus domains.
The study will compare the efficacy of Standard of Care (SOC) combined with CX-4945 against SOC paired with a placebo, utilizing a 1:1 allocation ratio in each domain.
Study Overview
Status
Not yet recruiting
Detailed Description
Domain I: SARS-CoV-2 domain
- Arm 1: CX-4945 (400 mg BID for 5 days) +SOC
- Arm 2: Placebo + SOC
Domain II: Influenza virus domain
- Arm 3: CX-4945 (400 mg BID for 5 days) +SOC
- Arm 4: Placebo + SOC
After screening visit, eligible subjects who fulfill all selection criteria for enrollment will be randomized into each of the arms. CX-4945 will be administered at 400 mg BID for up to 5 days. After treatment phase, subjects will be followed up for 28 days.
Study Type
Interventional
Enrollment (Estimated)
136
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Becky Lin
- Phone Number: +886-2-8911-9856
- Email: beckylin@senhwabio.com
Study Contact Backup
- Name: Hylee Lee
- Phone Number: +886-2-8911-9856
- Email: Hylee@senhwabio.com
Study Locations
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Not currently hospitalized.
- Males or non-pregnant females aged ≥ 18 years at the time of signing the informed consent form (ICF)
- Patients diagnosed with viral pneumonia, as determined by the investigator, who exhibit any of the subsequent criteria: presence of respiratory symptoms or fever.
- With a pneumonia severity index (PSI) of risk class II or III
- Oxygen saturation measured by pulse oximetry (SpO2) ≥94% on room air at sea level
- Positive test for SARS-CoV-2 or influenza virus infection by FilmArray; if FilmArray is not available, a positive test can also be confirmed by a rapid diagnostic test or molecular diagnostic assay, using a nasopharyngeal specimen
- Confirmed lower respiratory tract infection by X-ray.
- At screening, subjects capable of childbearing must provide a negative serum or urine pregnancy test. These subjects must also commit to adhering to the study-specified contraceptive methods throughout the study duration
- The participant (or legal representative) agrees to adhere to study protocols and has signed the IRB-approved Informed Consent Form (ICF)
- With at least two of the risk factors listed below: Age ≥ 50 years-old; cancer and a life expectancy of ≥ 6 months; HIV infection; immunocompromised patient; congestive heart failure (CHF), or coronary artery disease (CAD), or cardiomyopathies; chronic kidney disease (CKD); chronic liver disease; chronic lung disease; diabetes mellitus (DM); body mass index (BMI) > 25 kg/m2; asthma; cerebrovascular disease; cystic fibrosis; dementia; or current and former smoker.
Exclusion Criteria:
- Subject received investigational treatment within 30 days prior to the study, or concurrent use of another investigational drug.
- Subject has a history of severe renal disease (required phosphate binders or dialysis).
- Subject has chronic diarrhea, characterized by three or more loose stools daily for a minimum of four weeks.
- High likelihood of mortality within the next 48 hours, as assessed by the investigator.
- Subject showing signs of respiratory failure and mechanical ventilation is required.
- Subject with liver cirrhosis
- Subject with hepatitis B and/or hepatitis C disease, unless the subject has an aspartate aminotransferase (AST) level ranging from 8 to 31 U/L and an alanine aminotransferase (ALT) level from 0 to 41 U/L
- Known active tuberculosis.
- Current documented bacterial infection.
- Subject has a documented anaphylactic reaction, regardless of cause.
- Subject who has taken an antiviral agent against respiratory viral infection for a continuous duration of more than 24 hours before screening.
- Subject is with active gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
- Subjects received warfarin within 14 days prior to screening or intend to during the screening or treatment phase.
- History of allergic reactions to any of the ingredients or components used in the manufacture of CX-4945.
- Women who are pregnant or breastfeeding, or planning pregnancy during the study Notes: Men and women of reproductive potential must commit to effective contraception methods or abstinence during the study. Any resulting pregnancies or suspected pregnancies must be reported to the treating physician immediately.
- ALT or AST levels > 5 times upper limit of normal (ULN)
- eGFR < 30 mL/min/1.73m2 (calculated by the MDRD formula)
- Absolute neutrophil count (ANC) <1000/μL
- Have received treatment with a SARS-CoV-2 specific monoclonal antibody
- Have received convalescent COVID-19 plasma treatment
- Concurrent use of baricitinib
- Any physical findings or illness history that may compromise study results or increase patient risk, as determined by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SARS-CoV-2 domain: CX-4945 (400 mg BID for 5 days) +SOC
Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.
|
CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
Other Names:
|
Placebo Comparator: SARS-CoV-2 domain: Placebo + SOC
Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.
|
The dosage and frequency is the same as active drug.
|
Experimental: Influenza virus domain: CX-4945 (400 mg BID for 5 days) +SOC
Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.
|
CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.
Other Names:
|
Placebo Comparator: Influenza virus domain: Placebo + SOC
Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.
|
The dosage and frequency is the same as active drug.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of subjects requiring hospitalization, including emergency room visits, due to progression of CAP related to SARS-CoV-2 or influenza.
Time Frame: Day 1 to Day 29
|
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared to placebo plus SOC, in preventing the progression of CAP associated with SARS-CoV-2 and influenza virus infection
|
Day 1 to Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of subjects with all cause hospitalization during study period
Time Frame: Day 1 to Day 29
|
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition
|
Day 1 to Day 29
|
The percentage of subjects with improved pulmonary X-ray findings for pneumonia, relative to baseline or showing a return to normalcy
Time Frame: Day 1 to Day 5, 15, and 29
|
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition
|
Day 1 to Day 5, 15, and 29
|
Time to symptom resolution for fever. The symptom resolution for fever will be defined as body temperature of < 38°C.
Time Frame: Day 1 to Day 5
|
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition
|
Day 1 to Day 5
|
Change from baseline in SpO2/FiO2 ratio
Time Frame: Day 1 to Day 5, 15, and 29
|
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition
|
Day 1 to Day 5, 15, and 29
|
The percentage of subjects exhibiting disease progression in health status
Time Frame: Day 1 to Day 5, 15, and 29
|
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition
|
Day 1 to Day 5, 15, and 29
|
The percentage of subjects exhibiting disease improvement in health status
Time Frame: Day 1 to Day 5, 15, and 29
|
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in enhancing the subject's clinical condition
|
Day 1 to Day 5, 15, and 29
|
Change from baseline in viral load in nasal secretions by qRT-PCR. (only for SARS-CoV-2 domain)
Time Frame: Day 1 and Day 5
|
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in reducing viral load
|
Day 1 and Day 5
|
Time to FilmArray confirmed resolution of viral infection
Time Frame: Day 1 and Day 5
|
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in reducing viral load
|
Day 1 and Day 5
|
Change from baseline in Ct values (only for SARS-CoV-2 domain)
Time Frame: Day 1 and Day 5
|
To evaluate the effect of intervention with Silmitasertib (CX-4945) in addition to SOC, compared with placebo plus SOC, in reducing viral load
|
Day 1 and Day 5
|
TEAEs and SAEs
Time Frame: Day 1 to Day 29
|
To evaluate the safety and tolerability of Silmitasertib (CX-4945)
|
Day 1 to Day 29
|
Laboratory test
Time Frame: Day 1 to Day 29
|
To evaluate the safety and tolerability of Silmitasertib (CX-4945)
|
Day 1 to Day 29
|
Vital signs
Time Frame: Day 1 to Day 29
|
To evaluate the safety and tolerability of Silmitasertib (CX-4945)
|
Day 1 to Day 29
|
Electrocardiogram results
Time Frame: Day 1 to Day 29
|
To evaluate the safety and tolerability of Silmitasertib (CX-4945)
|
Day 1 to Day 29
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of subject s achieving normalized CRP levels.
Time Frame: Day 5
|
To evaluate the effect of intervention with Silmitasertib (CX 4945) in addition to SOC, compared with placebo plus SOC, on inflammatory status
|
Day 5
|
Change from baseline in ferritin, CRP, CAR, D-dimer, LDH, NLR, N4R, N3R, and PLR.
Time Frame: Day 1 to Day 5, 15 , and 29
|
To evaluate the effect of intervention with Silmitasertib (CX 4945) in addition to SOC, compared with placebo plus SOC, on inflammatory status
|
Day 1 to Day 5, 15 , and 29
|
Changes from baseline in serum cytokine levels: Cytokines to be quantified; IL-6, IL-1β, TNF-α, CCL2, IL 8 and IFN-γ.
Time Frame: Day 1 to Day 5, 15 , and 29
|
To evaluate the effect of intervention with Silmitasertib (CX 4945) in addition to SOC, compared with placebo plus SOC, on moderating the elevated cytokine release associated with SARS CoV 2 and Influenza virus infection
|
Day 1 to Day 5, 15 , and 29
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Jin-Ding Huang, PhD, Senhwa Biosciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 1, 2024
Primary Completion (Estimated)
March 1, 2025
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
January 1, 2024
First Submitted That Met QC Criteria
January 1, 2024
First Posted (Actual)
January 11, 2024
Study Record Updates
Last Update Posted (Actual)
January 11, 2024
Last Update Submitted That Met QC Criteria
January 1, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CX-4945-011
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Community-acquired Pneumonia
-
GlaxoSmithKlineTerminated
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineTerminated
-
GlaxoSmithKlineCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
Basilea PharmaceuticaCompletedCommunity-acquired Pneumonia (CAP) | Hospital-acquired Pneumonia (HAP)Bulgaria, Hungary, Georgia, Romania
-
Liverpool University Hospitals NHS Foundation TrustLiverpool School of Tropical MedicineCompletedCommunity Acquired Pneumonia | Lower Respiratory Tract Infection | Hospital Acquired PneumoniaUnited Kingdom
-
Future University in EgyptRecruitingCommunity-acquired PneumoniaEgypt
-
Nordsjaellands HospitalRecruitingCommunity-acquired PneumoniaDenmark
Clinical Trials on CX-4945 (SARS-CoV-2 domain)
-
Everly HealthCompletedSARS-CoV-2 Acute Respiratory DiseaseUnited States
-
Meshalkin Research Institute of Pathology of CirculationUnknown
-
Universidade Nova de LisboaRecruitingCoronavirus Infection | Pregnancy Complications | Breastfeeding | Neonatal Infection | Vertical Transmission of Infectious DiseasePortugal
-
Stemirna TherapeuticsNot yet recruiting
-
Stemirna TherapeuticsActive, not recruitingEfficacy | Safety | ImmunogenicityLao People's Democratic Republic
-
M.D. Anderson Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
Exact Sciences CorporationCompleted
-
Children's Hospital Medical Center, CincinnatiActive, not recruiting
-
Children's Hospital Medical Center, CincinnatiTerminatedCovid19 | SARS-CoV Infection | CoronavirusUnited States
-
NovafemCompletedSARS-CoV-2 Infection | Ovarian Reserve | BlastocystColombia